Free Trial

HC Wainwright Cuts Earnings Estimates for Gossamer Bio

Gossamer Bio logo with Healthcare background
Image from MarketBeat Media, LLC.

Key Points

  • HC Wainwright lowered its FY2030 EPS estimate for Gossamer Bio to $2.54 from $2.60, while maintaining a Buy rating.
  • Analyst opinions are mixed: MarketBeat reports a consensus Hold rating, with five Buy, three Hold, and two Sell recommendations.
  • Gossamer Bio reported a quarterly loss of $7.36 per share, wider than the $3.79 loss analysts expected; revenue of $38.43 million exceeded forecasts of $12.16 million.
  • MarketBeat previews the top five stocks to own by December 1st.

Gossamer Bio, Inc. (NASDAQ:GOSS - Free Report) - Equities research analysts at HC Wainwright reduced their FY2030 earnings per share estimates for shares of Gossamer Bio in a report issued on Friday, November 13th. HC Wainwright analyst P. Trucchio now expects that the company will post earnings of $2.54 per share for the year, down from their prior estimate of $2.60. HC Wainwright currently has a "Buy" rating on the stock. The consensus estimate for Gossamer Bio's current full-year earnings is ($27.13) per share.

Several other research analysts have also commented on the stock. Wedbush dropped their price objective on shares of Gossamer Bio to $32.00 and set a "neutral" rating for the company in a research note on Wednesday, November 11th. Wall Street Zen downgraded shares of Gossamer Bio from a "hold" rating to a "sell" rating in a research note on Sunday, September 20th. Chardan Capital reissued a "buy" rating on shares of Gossamer Bio in a research note on Monday, October 26th. Weiss Ratings lowered shares of Gossamer Bio from a "sell (d-)" rating to a "sell (e+)" rating in a report on Wednesday, November 4th. Finally, Leerink Partners raised shares of Gossamer Bio from a "market perform" rating to an "outperform" rating and set a $80.00 price target for the company in a research note on Tuesday, July 28th. Five equities research analysts have rated the stock with a Buy rating, three have given a Hold rating and two have assigned a Sell rating to the company. According to data from MarketBeat.com, the company currently has a consensus rating of "Hold" and an average price target of $246.40.

Get Our Latest Stock Analysis on GOSS

Gossamer Bio Price Performance

Shares of GOSS opened at $10.97 on Monday. The company has a market cap of $67.14 million, a PE ratio of -0.24 and a beta of 2.28. The business has a fifty day moving average of $10.56 and a 200 day moving average of $32.93. Gossamer Bio has a 52-week low of $8.29 and a 52-week high of $309.60.

Gossamer Bio (NASDAQ:GOSS - Get Free Report) last released its earnings results on Tuesday, November 10th. The company reported ($7.36) earnings per share for the quarter, missing the consensus estimate of ($3.79) by ($3.57). The firm had revenue of $38.43 million during the quarter, compared to analysts' expectations of $12.16 million.

Institutional Investors Weigh In On Gossamer Bio

Several hedge funds and other institutional investors have recently modified their holdings of the business. Corient Private Wealth LP lifted its stake in shares of Gossamer Bio by 41.3% during the 2nd quarter. Corient Private Wealth LP now owns 5,632,698 shares of the company's stock worth $927,000 after acquiring an additional 1,647,315 shares during the last quarter. Hsbc Holdings PLC boosted its holdings in Gossamer Bio by 1,289.4% during the 2nd quarter. Hsbc Holdings PLC now owns 1,583,118 shares of the company's stock valued at $267,000 after acquiring an additional 1,469,175 shares during the period. Bank of America Corp DE purchased a new position in Gossamer Bio during the 2nd quarter valued at $65,000. Hhlr Advisors LTD. purchased a new position in Gossamer Bio during the 2nd quarter valued at $819,000. Finally, ARCH Venture Management LLC bought a new position in Gossamer Bio in the 2nd quarter valued at $1,326,004. 81.23% of the stock is currently owned by hedge funds and other institutional investors.

About Gossamer Bio

(Get Free Report)

Gossamer Bio, Inc. is a clinical-stage biopharmaceutical company headquartered in San Diego, California. The company develops medicines for serious diseases, with a focus on pulmonary vascular conditions. Its lead candidate is seralutinib, an inhaled investigational therapy being studied for pulmonary arterial hypertension and pulmonary hypertension associated with interstitial lung disease. Seralutinib is not an approved medicine. Gossamer has partnered with Chiesi Group to advance its development.

See Also

Earnings History and Estimates for Gossamer Bio (NASDAQ:GOSS)

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Should You Invest $1,000 in Gossamer Bio Right Now?

Before you consider Gossamer Bio, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Gossamer Bio wasn't on the list.

While Gossamer Bio currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

The 7 Hottest IPO Stories of 2026 Cover

MarketBeat just released its list of the 7 hottest IPOs expected to hit Wall Street in 2026. See which companies are preparing to go public and why investors are watching closely.

Get This Free Report
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Like this article? Share it with a colleague.

Featured Articles and Offers

Recent Videos

Stock Lists

All Stock Lists

Investing Tools

Calendars and Tools

Search Headlines